Legal Opinion
Neptune Generics, LLC v. Eli Lilly & Company
Court of Appeals for the Federal Circuit
Decided April 26, 2019No. 2018-1257; 2018-1258; 2018-1288; 2018-1290PublishedCited by 12 opinions
1Opinion of the Court
Moore, Circuit Judge.
*1374 Neptune Generics, LLC, Fresenius Kabi USA, LLC, and Mylan Laboratories Ltd. ("Petitioners") appeal the Patent Trial and Appeals Board's inter partes review ("IPR") decisions holding Petitioners did not establish that claims 1-22 of U.S. Patent No. 7,772,209 are unpatentable for obviousness. Because the Board did not err in its obviousness analysis, substantial evidence supports its underlying fact findings, and subject matter eligibility is not properly before the court in an appeal from an IPR decision, we affirm.
BACKGROUND
The '209 patent is owned by Eli Lilly & Co. and…
2Cases cited7 opinions
- KSR International Co. v. Teleflex Inc.Supreme Court of the United States · 2007
- Wbip, LLC v. Kohler Co.Court of Appeals for the Federal Circuit · 2016
- Arctic Cat Inc. v. Bombardier Recreational Products Inc.Court of Appeals for the Federal Circuit · 2017
- Intelligent Bio-Systems, Inc. v. Illumina Cambridge Ltd.Court of Appeals for the Federal Circuit · 2016
- Belden Inc. v. Berk-Tek LLCCourt of Appeals for the Federal Circuit · 2015
2 more not listed; retrieve them via the Exa API.
3Cited by12 opinions
- Eli Lilly and Company v. Hospira, Inc.Court of Appeals for the Federal Circuit · 2019
- Cephalon, Inc. v. Slayback Pharma Limited Liability CompanyDistrict Court, D. Delaware · 2020
- JANSSEN PHARMACEUTICALS, INC. v. MYLAN LABORATORIES LIMITEDDistrict Court, D. New Jersey · 2023
- Medline Industries, Inc. v. C.R. Bard, Inc.District Court, N.D. Illinois · 2020
- MyMail, Ltd. v. ooVoo, LLCDistrict Court, N.D. California · 2020
7 more not listed; retrieve them via the Exa API.